INFU earnings analysis
What we found in INFU's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
InfuSystem delivered Q2 revenue of $36.933 million, up 2.6% year over year and 9.6% sequentially, while diluted EPS improved to $0.15 from $0.12 a year ago and $0.05 in Q1. Margin performance was favorable, with gross margin up 2.8 percentage points to 58.0% and operating margin reaching 11.2%, supported by Device Solutions cost actions. However, Patient Services growth was offset by a 16.1% Device Solutions contraction, and first-half cash conversion weakened as accounts receivable rose $5.7 million and cash fell to $0.964 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue returned to sequential growth
- Q2 revenue was $36.933 million, up $0.931 million (+2.6%) from $36.002 million a year ago and up $3.249 million (+9.6%) sequentially from first-half revenue less Q2 revenue of $33.684 million. Revenue exceeded the $36.382 million consensus estimate.
- EPS and net income accelerated
- Diluted EPS rose to $0.15 from $0.12 in Q2 2025 and $0.05 in Q1 2026; net income increased $0.632 million to $3.231 million. EPS was $0.04 above the $0.11 consensus estimate.
- Margin expansion lifted profitability
- Gross margin expanded 2.8 percentage points year over year to 58.0%, lifting gross profit 7.7% to $21.413 million. Operating income increased $0.375 million to $4.152 million, producing an 11.2% operating margin versus 10.5% a year earlier.
- Patient Services growth offset device weakness
- Patient Services revenue grew $3.270 million (+15.2%) to $24.788 million, driven by Oncology growth of $1.2 million (+6.4%) and Wound Care growth of $2.1 million (+154%).
- Device margin gains offset lower sales
- Device Solutions gross profit held at $6.101 million despite a $2.339 million revenue decline, as segment gross margin rose 8.3 percentage points to 50.2%. The GE Healthcare contract restructuring reduced expenses more than related revenue.
- Operating cash generation and buyback authorization
- The company generated $7.747 million of operating cash flow in the first six months and authorized a new $20.0 million repurchase program running from July 1, 2026 through June 30, 2028.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Device Solutions remains in steep decline
- Device Solutions revenue fell $2.339 million (-16.1%) to $12.145 million. Biomedical-services revenue declined $1.8 million (-39.4%), including $1.6 million from reduced GE Healthcare contract volume and service levels.
- Cash balance fell while revolver use rose
- Cash and cash equivalents declined to $0.964 million at June 30, 2026 from $3.186 million at December 31, 2025, while revolving-facility draws increased to $20.757 million from $20.000 million.
- Receivables and working capital pressured cash
- Operating cash flow decreased $1.042 million to $7.747 million in the first half as working capital consumed $7.1 million, including a $5.7 million accounts-receivable increase and a $2.6 million reduction in accounts payable and other liabilities.
- Patient Services mix diluted segment margin
- Patient Services gross margin declined 2.4 percentage points year over year to 61.8% due to a mix shift toward lower-margin Wound Care revenue and higher pump-maintenance expense.
- Operating-cost inflation remains a headwind
- Selling and marketing expense rose $0.285 million (+10.5%) to $2.989 million and G&A rose $0.951 million (+7.2%) to $14.097 million, reflecting headcount, stock compensation, wage inflation and elevated healthcare costs.
- No updated Item 1A risk disclosures
- No risk-factor changes were reported: Item 1A refers investors to the risk factors in the February 27, 2026 Form 10-K. The filing nevertheless identifies $20.0 million of interest-rate derivative notional value and a 5.66% weighted-average Term Benchmark borrowing rate at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.15
- Gross margin
- 58.0%
- Operating margin
- 11.2%
- Segment
- Patient Services revenue: $24.788 million, up $3.270 million (+15.2%) year over year.
- Segment
- Device Solutions revenue after intersegment eliminations: $12.145 million, down $2.339 million (-16.1%) year over year.
What they said about what is next.
The 10-Q contains no explicit quantitative revenue or EPS guidance. Management states it believes $55.207 million of available liquidity is adequate for at least the next year, while noting future funding needs could require debt or equity financing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2026
- InfuSystem reported Q1 2026 earnings with revenues of $33.7 million, missing estimates by 2.6% while EPS exceeded estimates by 25%. The Patient Services segment saw a robust growth of 6.4%, mainly due to increased…
- 10-K · February 27, 2026
- InfuSystem positions itself as a two-platform DME services provider (Patient Services and Device Solutions) focused on clinic-to-home infusion therapy, with a lead Oncology Business that generated ~87% of Patient…
- 10-Q · May 8, 2025
- InfuSystem reported Q1 2025 revenue of $34,716,000 (up $2,721,000 or ~8.5% vs Q1 2024) and delivered operating income of $618,000 versus an operating loss of $(845,000) a year ago. Gross margin expanded to 55.2% and…
- 10-K · March 11, 2025
- InfuSystem’s 10-K (fiscal year ended December 31, 2024) describes a two-platform strategy (Patient Services and Device Solutions) focused on clinic-to-home infusion therapy with a durable moat built from payer…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INFU makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever